DBVT · DBV Technologies S.A. · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EUR | — | — | — | — | — | — | — | — | — | — | — | 128K |
| $43.79M | $32.79M | $28.74M | $29.5M | $24.32M | $30.52M | $35.08M | $49.07M | — | — | — | — | |
| — | — | — | — | — | $0 | $23.55M | — | — | — | — | — | |
| $182.79M | $152.69M | $120.74M | $92.16M | $101.48M | $104.32M | $170.12M | $185.73M | — | — | — | — | |
| EUR | — | — | — | — | — | — | — | 1.41M | 351K | 3.33M | 16K | 146K |
| — | -$146.95M | -$113.92M | -$72.73M | -$96.27M | -$97.81M | -$159.56M | -$172.01M | — | — | — | — | |
| -$182.29M | -$140.19M | -$117.98M | -$67.05M | -$104.44M | -$110.07M | -$136.08M | -$172.38M | — | — | — | — | |
| USD/shares | -$0.71 | -$1.05 | -$1.17 | -$0.76 | -$2.48 | -$3.56 | — | — | — | — | — | — |
| USD/shares | -$0.71 | -$1.05 | -$1.17 | -$0.76 | -$2.48 | -$3.56 | — | — | — | — | — | — |
| shares | — | 139.57M | 97M | 95.12M | 38.69M | 27.46M | 27.05M | 18.5M | — | — | — | — |
| shares | — | 139.57M | 97M | 95.12M | 38.69M | 27.46M | 27.05M | 18.5M | — | — | — | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2015–FY2018: $733K in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 302 similar-size Biotechnology companies (of 534 listed).